NuCana (NASDAQ:NCNA) Stock Price Down 4.8% – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price was down 4.8% during mid-day trading on Tuesday . The stock traded as low as $2.89 and last traded at $2.95. Approximately 76,073 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 78,638 shares. The stock had previously closed at $3.10.

Analyst Ratings Changes

NCNA has been the topic of a number of research reports. Wall Street Zen upgraded shares of NuCana from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

NuCana Stock Down 4.8%

The stock has a market cap of $88,500.00, a P/E ratio of -0.02 and a beta of 1.60. The stock has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $4.77.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.69) by $2.59. Sell-side analysts anticipate that NuCana PLC Sponsored ADR will post -13.42 earnings per share for the current year.

Hedge Funds Weigh In On NuCana

A hedge fund recently raised its stake in NuCana stock. FNY Investment Advisers LLC lifted its position in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.00% of the company’s stock.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.